^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

COMPANY:
PreludeDx

i
Other names: PreludeDx
Related tests:
Evidence

News

19d
PreludeDx announces new contract with MediNcrease Health Plans for its novel DCIS test, DCISionRT® (PreludeDx Press Release)
"Prelude Corporation...announced it has entered into a managed care provider agreement with MediNcrease Health Plans, a national provider network in the US, to make accessible the PreludeDx’s DCISionRT test to its clients and payers. Under the agreement, MediNcrease’s clients and payers, providers, and their patients throughout the U.S. will now have access to DCISionRT, the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy (RT) benefit."
Clinical
|
DCISionRT
20d
PreludeDx Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone (PRNewswire)
"Prelude Corporation...announced it will be presenting data comparing risk stratification and radiation benefit (RT) for patients with ductal carcinoma in situ (DCIS) using DCISionRT™ with a clinicopathologic (CP) model similar to the Memorial Sloan Kettering Cancer Center (MSKCC) DCIS nomogram at the 40th Annual Miami Breast Cancer Conference (MBCC), being held on March 2 – 5, 2023 at the Fontainebleau Miami Beach....The study included 926 DCIS patients from four cohorts who were treated with breast conserving surgery (BCS) or BCS + radiation therapy (RT). The study compared MSKCC DCIS nomogram-like model with the DCISionRT 7-gene biosignature."
Clinical data
|
DCISionRT
2ms
PreludeDx enters into agreement with Medical Cost Containment Professionals, LLC to process out-of-network claims for its novel DCIS test, DCISionRT® (PreludeDx Press Release)
"Prelude Corporation...announced it has entered into a managed care provider agreement with Medical Cost Containment Professionals LLC (MCCP) to process out-of-network claims for PreludeDx’s DCISionRT test. Under the agreement, MCCP’s more than 150,000 providers nationwide and their patients throughout the U.S. will now have access to DCISionRT, the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy (RT) benefit."
Licensing / partnership
|
DCISionRT
3ms
PreludeDx DCISionRT Data Presented in Spotlight Presentation at the 2022 San Antonio Breast Cancer Symposium (PreludeDx Press Release)
P=NA | N=926 | "Prelude Corporation...announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior recurrence risk stratification and radiation therapy (RT) benefit prediction compared to commonly used clinicopathologic (CP) features...This study....revealed in 926 women from four cohorts, that DCISionRT was a superior predictor of 10-year IBR rates and RT benefit compared to clinicopathologic criteria. DCISionRT identified that approximately half of CP-Low Risk patients were classified as elevated risk by the test and significantly benefited from RT with an absolute 17.7% reduction in 10-year ipsilateral breast recurrence. Whereas DCISionRT Low Risk patients, which included about one-third of CP High-Risk patients, had no significant RT benefit, representing a true low risk group."
Clinical data
|
DCISionRT
4ms
PreludeDx Announces Latest Data on DCISionRT in Multiple Presentations at the 2022 San Antonio Breast Cancer Symposium (PreludeDx Press Release)
"Prelude Corporation...announced today that data will be presented in four separate poster presentations at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held on December 6 – 10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX. Presentations will include a spotlight poster on DCISionRT and its identification of a low-risk group of DCIS patients with no benefit from adjuvant radiation, a poster addressing the role of DCISionRT in treatment implications for HER2(+) patients, and two separate presentations on the latest data in the Predict Registry studies from both the U.S. and Australia."
P3 data
|
DCISionRT
5ms
GenesisCare and PreludeDx(TM) present compelling Australian-first DCISionRT study interim analysis during breast cancer awareness month 45% change in treatment recommendations when using DCISionRT (PRNewswire)
"GenesisCare...announced interim results from the AUSPREDICT registry. Data presented at the Australasian International Breast Congress demonstrates a significant (45%) change in radiation therapy treatment recommendations1 when using the DCISionRT test, optimising management to prevent over and under treatment of Australian women with Ductal Carcinoma In Situ (DCIS)."
Clinical data
|
DCISionRT
5ms
PreludeDx Presents DCISionRT Data in Oral Presentation at the American Society for Radiation Oncology Annual Meeting (PreludeDx Press Release)
"Prelude Corporation...announced study results demonstrating that DCISionRT provides patients with ductal carcinoma in situ (DCIS) superior risk and RT benefit prediction compared to common clinicopathologic features....This study...highlighted that clinicopathologic criteria were poor predictors of 10-year ipsilateral breast recurrence (IBR) rates and radiation therapy (RT) benefit in 926 women from four international cohorts."
Clinical data
|
DCISionRT
5ms
PreludeDx to Present DCISionRT and Novel Residual Risk Subtype Prospective Data During Scientific Oral Session at ASTRO 2022 Annual Meeting (PreludeDx Press Release)
"Prelude Corporation..announced today that its prospective data of 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the 64th Annual American Society for Radiation Oncology (ASTRO) Meeting, to be held on October 23 – 26, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, TX."
Clinical data
|
DCISionRT
6ms
PreludeDx Announces Publication of Residual Risk after Radiation Therapy Data in the International Journal of Radiation Oncology•Biology•Physics (PreludeDx Press Release)
P=NA | N=926 | "Prelude Corporation...announced the publication of clinical study data in the International Journal of Radiation Oncology· Biology· Physics ('Red Journal'). The study demonstrated that the DCISionRT® Residual Risk Subtype (RRt) identified ductal carcinoma in situ (DCIS) patients who had a much higher recurrence risk following breast conserving surgery (BCS) and radiation therapy (RT)....This study...evaluated 10-year recurrence risk in 926 women diagnosed with DCIS and treated with BCS with or without RT. Patients in the RRt group had a 42% risk of recurrence after BCS and a significantly elevated recurrence rate of 14.7% after BCS and RT."
Clinical data
|
DCISionRT
6ms
PreludeDx presents new data at AACR confirming no significant radiation benefit in DCISionRT low-risk patients (PreludeDx Press Release)
"Prelude Corporation...announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS) identifying patients with low risk of recurrence independent of traditional clinicopathologic risk factors. Study results were presented today at the American Association for Cancer Research (AACR) Special Conference: Rethinking DCIS: An Opportunity for Prevention...The DCISionRT® test demonstrated that radiation did not significantly reduce the in-breast recurrence (IBR) rate in the low-risk group. However, the elevated/residual-risk group benefited significantly from radiation therapy (RT), with a 17.7% absolute 10-year IBR rate reduction."
Clinical data
|
DCISionRT
7ms
PreludeDx announces preferred provider agreement with Galaxy Health Network for its novel DCIS Test, DCISionRT (PreludeDx Press Release)
"Prelude Corporation (PreludeDx)...announced...that it has signed an agreement with Galaxy Health Network to provide coverage for the company’s novel DCISionRT test for ductal carcinoma in situ (DCIS), also known as stage zero breast cancer. Under the agreement, Galaxy’s more than 3.5 million members and over 400,000 providers will now have access to DCISionRT."
Licensing / partnership
|
DCISionRT
8ms
PreludeDx Enters into Preferred Provider Agreement with Three Rivers Provider Network for its Novel DCIS test, DCISionRT (PreludeDx Press Release)
"Prelude Corporation...announced today that it has signed an agreement with Three Rivers Provider Network, Inc. (TRPN)...Under the agreement, TRPN's more than 200 million members will now have access to DCISionRT."
Licensing / partnership
|
DCISionRT
10ms
PreludeDx presents new DCISionRT data on the effectiveness of endocrine therapy in DCIS patients at the ASCO 2022 Annual Meeting (PreludeDx Press Release)
"Prelude Corporation...announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral abstract session at the American Society of Clinical Oncology (ASCO) Annual Meeting at McCormick Place, Chicago, IL...The results of the study demonstrated that after breast conserving surgery (BCS) patients in the DCISionRT elevated risk group had a significant risk reduction from endocrine therapy (ET), while those patients in the DS low risk group did not have a significant risk reduction from ET."
Clinical data
|
DCISionRT
10ms
PreludeDxTM to present DCIS study results assessing benefit of adjuvant endocrine therapy using DCISionRT during oral presentation at ASCO 2022 Annual Meeting (PreludeDx Press Release)
"Prelude Corporation...announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT was selected for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting. The results evaluating the association of DCISionRT, a predictive DCIS Biosignature to assess the impact of Endocrine Therapy (ET) on 10-year ipsilateral breast recurrence (IBR) risk after breast conserving surgery alone or with radiation therapy (RT), will be presented on June 7, 2022 at McCormick Place, Chicago, IL."
Clinical data
|
DCISionRT
11ms
PreludeDx presents compelling DCISionRT study results in young and high-grade DCIS patients at ASBrS 2022 Annual Meeting (PreludeDx Press Release)
"Prelude Corporation...announced compelling results in 926 women diagnosed with ductal carcinoma in situ (DCIS). The new information was presented in an oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting, held on April 6 - 10, 2022 at Wynn Las Vegas, NV...DCISionRT identified women with a low 5% 10-yr risk of recurrence with or without radiation therapy: overall and within either high-grade or young patients. Furthermore, the test predicted which patients had a superior benefit from radiation therapy (>70% relative risk reduction)."
Clinical data
|
DCISionRT
12ms
PreludeDxTM to present DCISionRT and novel residual risk subtype study results during scientific oral session at ASBrS 2022 Annual Meeting (PreludeDx Press Release)
"Prelude Corporation...announced today that its study in 926 patients demonstrating the clinical utility of DCISionRT and its Residual Risk Subtype (RRt) was selected for a scientific session oral presentation at the American Society of Breast Surgeons (ASBrS) 23rd Annual Meeting. The results assessing 10-year risk of ipsilateral breast recurrences in patients with grade 3 ductal carcinoma in situ (DCIS) disease and/or young age (<50 years) treated with breast conserving surgery (BCS) with or without radiation therapy (RT), will be presented on April 9, 2022 at Wynn Las Vegas, NV."
Clinical data
|
DCISionRT
12ms
PreludeDxTM closes $20 million in funding to advance growth initiatives and development of its precision medicine portfolio (PreludeDx Press Release)
"Prelude Corporation...announced that it has closed a $20 million funding round led by Evidity Health Capital and joined by existing and new investors...Proceeds from this round will be used to advance the commercial market expansion of DCISionRT and the continued development of the company’s precision radiogenomics platform for early-stage breast cancer and other cancers."
Financing
|
DCISionRT
1year
PreludeDx presents DCIS patient data comparing clinicopathological risk factors to DCISionRT (PreludeDx Press Release)
"Prelude Corporation (PreludeDx), announced it will be presenting data comparing DCISionRT and its integrated Residual Risk subtype (RRt) with traditional clinicopathology features at the 39th Annual Miami Breast Cancer Conference (MBCC), being held on March 3 – 6, 2022 at the Fontainebleau Miami Beach...The poster is entitled, ‘Clinicopathological Risk Factors Poorly Stratified Baseline Risk and RT benefit Compared to DCISionRT in Patients with Ductal Carcinoma in Situ’ and will be available online for viewing during the duration of the conference and available in-person during the poster receptions on March 3rd and 4th."
Clinical data
|
DCISionRT
over1year
PreludeDx DCISionRT predicts radiation benefit in landmark randomized SweDCIS clinical trial (PreludeDx Press Release)
"Prelude Corporation...announced the publication of SweDCIS randomized clinical trial data in the Special Issue Updates on Breast Cancer edition of Cancers. The randomized study demonstrates that the DCISionRT test predicts radiation benefit for reducing 10-year local invasive breast cancer risk...The study assessed 10-yr outcomes in 504 women treated with breast conserving surgery (BCS) and randomized into RT or no RT arms. Patients in the DCISionRT elevated risk group had a 9% significant reduction in invasive risk from radiation therapy. While women in the low risk group had a 1% non-significant difference after receiving radiation therapy. The results are highly consistent with three prior DCISionRT studies, further validating the predictive value of the assay."
Clinical data
|
DCISionRT
over1year
DCISionRT® demonstrates 40 percent change in radiation therapy treatment recommendation for DCIS patients (PreludeDx Press Release)
"Prelude Corporation...announced today it will be presenting new data on its ongoing prospective PREDICT study of DCIS patients at the 2021 San Antonio Breast Cancer Symposium (SABCS), being held on December 7 – 10 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. PreludeDx will present scientific data demonstrating a significant (40%) change in radiation therapy (RT) treatment recommendations when using the DCISionRT test."
Clinical data
|
DCISionRT
over1year
American Medical Association grants PreludeDxTM a CPT PLA code for proprietary DCISionRT Test (PreludeDx Press Release)
"Prelude Corporation (PreludeDx)...announced today that the American Medical Association (AMA) has issued a new, dedicated Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) code for DCISionRT, the only test available to predict personalized recurrence risk and radiation therapy benefit for patients with ductal carcinoma in situ (DCIS). The new code 0295U, will become effective January 1, 2022 and is specific to the DCISionRT test."
Clinical
|
DCISionRT
almost2years
PreludeDx enters into preferred provider agreement with MultiPlan, Inc. (PreludeDx Press Release)
"Prelude Corporation (PreludeDx)...announced today that it has entered into an agreement with MultiPlan, Inc., the nation’s leading provider of healthcare cost management solutions to participate in MultiPlan’s primary (PHCS) and complementary (MultiPlan) networks. Under terms of the agreement, more than 60 million members and nearly 1 million providers will have access to DCISionRT at discounted rates. DCISionRT a DCIS radio-genomic test, is the only test to predict personalized recurrence risk and radiation therapy benefit for patients with ductal carcinoma in situ (DCIS)."
Licensing / partnership
|
DCISionRT
almost2years
Fourth validation of DCISionRT by PreludeDx predicts risk of breast cancer recurrence and radiation benefit for DCIS patients after surgery (PreludeDx Press Release)
"Prelude Corporation (PreludeDx)...presented data at the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care. The study validated the clinical utility of the DCISionRT® biosignature to assess ipsilateral breast event (IBE) risk after breast conserving surgery (BCS) and the benefit of radiation therapy (RT). Women with ductal carcinoma in situ (DCIS) and Elevated Decision Scores (DS) had a significantly higher risk of IBE and a greater relative benefit from RT compared to women with lower DS."
Clinical
|
DCISionRT
2years
DCISionRT® by PreludeDx™ identifies DCIS breast cancer patients at increased risk for breast cancer specific death (PRNewswire)
"Prelude Corporation (PreludeDx™)…presented data at the Miami Breast Cancer Conference (MBCC) 2021 Annual Meeting examining the association of DCISionRT® test results with breast cancer mortality (BCM) in patients diagnosed with ductal carcinoma in situ (DCIS). Study results demonstrated patients with higher DCISionRT scores had an increased risk of BCM... The primary endpoint of the study was to identify the association of DCISionRT test results with breast cancer mortality. DCISionRT Decision Score (DS) results were available for 157 of the 414 women. Primary DCIS was treated with breast conserving surgery (BCS) alone, BCS plus radiotherapy or mastectomy in 34%, 29% and 37% of the cases, respectively. Results revealed patients with increasing continuous DS had increasing BCM (OR=10, p=0.004), and patients with high categorical DS (>6) were at greater risk of BCM (OR=19, p=0.007)."
Clinical
|
DCISionRT
2years
GenesisCare and PreludeDx™ partner to provide access to groundbreaking precision medicine test for women with early-stage breast cancer (PreludeDx Press Release)
"GenesisCare...and Prelude Corporation (PreludeDx™)...today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes...The new partnership between GenesisCare and PreludeDx will make DCISionRT testing available in Australia, where the test is currently not offered, as well as increase patient access in the United States through GenesisCare’s network of integrated cancer treatment centers. Australian-headquartered GenesisCare is one of the largest networks of integrated oncology care in the world, with more than 440 treatment centers and clinics across the US, Australia, the UK, and Spain."
Licensing / partnership
|
DCISionRT
over2years
PreludeDx presents new data at SABCS spotlight session re-classifying patients meeting RTOG 9804 low risk criteria as elevated risk using DCISionRT (PreludeDx Press Release)
"Prelude Corporation (PreludeDx)…presented clinical outcomes data last week at the San Antonio Breast Cancer Symposium (SABCS) that further validates the DCISionRT test results of an independent study by Kaiser Permanente Northwest published earlier this year in Clinical Cancer Research…‘In this study we examined the utility of the DCISionRT test to identify patients who otherwise met traditional ‘good-risk’ criteria but remained at an elevated invasive risk after lumpectomy…’"
Clinical
|
DCISionRT
over2years
PreludeDx™ announces partnership with America's Choice Provider Network (PreludeDx Press Release)
"Prelude Corporation (PreludeDx™)…announced today that it has signed an agreement to become a provider in the America's Choice Provider Network (ACPN). Under terms of the agreement, more than 30 million ACPN members from across the U.S. will have access and coverage for DCISionRT, the only DCIS Radio Genomic test that offers personalized recurrence risk and radiation therapy treatment benefit for patients with ductal carcinoma in situ (DCIS)."
Licensing / partnership
|
DCISionRT